GlassScriptPhysician profile
Amanda J Mckenzie
NPI 1811215874
$8,837.64
in general payments reported to CMS, 2019-2025
52 companies · $1,909 in 2025
The $1,909 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.65 · 2022: $231 · 2023: $1,201 · 2024: $5,465 · 2025: $1,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,562 · Consulting Fee: $2,000 · Travel and Lodging: $913 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,561.51 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $912.67 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,597.14 | 2024 | Xifaxan, Relistor, Trulance |
| Novartis Pharmaceuticals Corporation | $599.56 | 2023-2025 | |
| Janssen Biotech, INC. | $384.19 | 2021-2025 | Darzalex, Talvey, Imbruvica |
| Astrazeneca Pharmaceuticals LP | $323.17 | 2023-2025 | Calquence, Tagrisso, Imfinzi |
| Abbvie INC. | $270.54 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $267.50 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $242.17 | 2024-2025 | Keytruda, Keytruda Qlex, Reblozyl |
| Genzyme Corporation | $227.75 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $181.40 | 2023-2024 | Fotivda |
| Incyte Corporation | $163.94 | 2021-2025 | Monjuvi, Pemazyre, Zynyz |
| Daiichi Sankyo INC. | $154.62 | 2022-2025 | Enhertu, Datroway |
| Tersera Therapeutics LLC | $146.56 | 2023-2025 | Zoladex |
| Alexion Pharmaceuticals, INC. | $142.04 | 2022-2025 | Ultomiris |
| Eisai INC. | $139.23 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $127.80 | 2022-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $122.35 | 2023-2025 | Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $110.55 | 2023-2024 | Ninlaro, Iclusig |
| Sobi, INC | $103.94 | 2025 | |
| Taiho Oncology, INC. | $90.03 | 2023-2025 | |
| Genentech USA, INC. | $87.59 | 2023-2025 | Phesgo, Perjeta, Venclexta |
| Emd Serono, INC. | $85.30 | 2024-2025 | |
| Exelixis INC. | $84.25 | 2024-2025 | Cabometyx |
| Puma Biotechnology, INC. | $74.03 | 2024-2025 | |
| Genmab U.S., INC. | $73.50 | 2024-2025 | Epkinly |
| Pfizer INC. | $67.80 | 2024-2025 | |
| Pharmaessentia USA Corporation | $67.51 | 2024-2025 | Besremi |
| Adc Therapeutics America, INC. | $67.12 | 2024-2025 | |
| Beigene USA, INC. | $64.57 | 2023-2024 | Brukinsa |
| Karyopharm Therapeutics INC. | $54.42 | 2024-2025 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $50.39 | 2023-2024 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.64 | 2024 | Gilotrif |
| G1 Therapeutics, INC. | $45.36 | 2022-2023 | Cosela |
| Blueprint Medicines Corporation | $43.88 | 2024 | Ayvakit |
| Celgene Corporation | $41.80 | 2025 | Reblozyl |
| Stemline Therapeutics INC. | $40.99 | 2024-2025 | Orserdu |
| Agios Pharmaceuticals, INC. | $38.02 | 2024-2025 | Pyrukynd |
| Astellas Pharma US INC | $37.78 | 2022-2023 | Xtandi |
| Mirati Therapeutics, INC. | $37.48 | 2023 | Krazati |
| Pharmacosmos Therapeutics INC. | $32.75 | 2024-2025 | Monoferric |
| Adaptive Biotechnologies Corporation | $32.74 | 2025 | Clonoseq |
| Amgen INC. | $29.94 | 2023 | Vectibix, Nplate, Xgeva |
| Rigel Pharmaceuticals, INC. | $25.90 | 2024 | Rezlidhia, Tavalisse |
| Sumitomo Pharma America, INC. | $25.54 | 2024 | Orgovyx |
| Ipsen Biopharmaceuticals, INC | $24.20 | 2024 | Somatuline Depot, Onivyde |
| Pharmacyclics LLC, An Abbvie Company | $23.66 | 2023 | Imbruvica |
| Beone Medicines USA, INC. | $23.17 | 2025 | Brukinsa |
| Verastem, INC. | $21.63 | 2025 | Avmapki Fakzynja Co-Pack |
| Glaxosmithkline, LLC. | $19.67 | 2025 | Zejula, Jemperli |
| Lilly USA, LLC | $19.32 | 2024 | Verzenio |
| Iovance Biotherapeutics, INC. | $19.21 | 2025 | Amtagvi |
| Morphosys, US INC. | $17.50 | 2023 | Monjuvi |
| Deciphera Pharmaceuticals INC. | $17.50 | 2024 | Qinlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.